# Andrew J. Wagner

Source: https://onco.cc/people/andrew-wagner/  
OnCo record `andrew-wagner` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Boston sarcoma doctor who first showed that mTOR inhibitors shrink perivascular epithelioid cell tumours and then led AMPECT, the trial that made nab-sirolimus the first approved treatment for these rare cancers.

## Summary

Andrew Wagner is a medical oncologist in the sarcoma centre at Dana-Farber Cancer Institute. He was first author of the 2010 Journal of Clinical Oncology report showing responses to sirolimus in malignant perivascular epithelioid cell tumours, linking their TSC1/TSC2 loss to mTOR dependence, and of the 2021 Journal of Clinical Oncology report of AMPECT, the phase 2 trial in which nab-sirolimus produced durable responses in advanced malignant PEComa, the basis of the first approval for the disease.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: sarcoma; rare-cancers; targeted-therapy; trialist
- Role: Sarcoma medical oncologist, Dana-Farber Cancer Institute
- Specialisms: PEComa; mTOR inhibitors; Rare sarcomas

## Connected records

- cancers: [Perivascular epithelioid cell tumour (PEComa)](https://onco.cc/cancers/pecoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- institutions: [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/)
- key papers: [AMPECT: nab-sirolimus for malignant perivascular epithelioid cell tumours](https://onco.cc/key-papers/paper-ampect-nab-sirolimus-pecoma-wagner-jco-2021/), [Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumours](https://onco.cc/key-papers/paper-wagner-sirolimus-pecoma-jco-2010/)

---
JSON: https://onco.cc/api/v1/entities/andrew-wagner.json